MucoRice CTB - Astellas/The Institute of Medical Science, The University of Tokyo

Drug Profile

MucoRice CTB - Astellas/The Institute of Medical Science, The University of Tokyo

Alternative Names: MucoRice-CTB

Latest Information Update: 29 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute of Medical Science, The University of Tokyo
  • Developer Astellas Pharma; Institute of Medical Science, The University of Tokyo
  • Class Cholera vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Cholera
  • Research Escherichia coli infections

Most Recent Events

  • 06 Dec 2017 Clinical development is ongoing in Japan
  • 06 Dec 2017 The Institute of Medical Science, the University of Tokyo (IMSUT), Chiba University, Astellas Pharma and Asahi Kogyosha collaborate on MucoRice
  • 22 Jun 2016 The Institute of Medical Science, the University of Tokyo (IMSUT) and Astellas Pharma agree to co-develop MucoRice CTB in Japan for Cholera and Escherichia coli infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top